I am an Associate Professor of Biochemistry and one of the Coordinators of the Biology Area at FAPESP and CNPq. I lead the Laboratory of Neuroproteomics since 2014, when I returned from Germany after a period of 2 years as Principal Investigator at LMU - Ludwig Maximilians Universität Muenchen (12-14). My expertise is mainly in mass spectrometry-based proteomics (shotgun proteomics) and systems biology in silico, employed to clinical and pre-clinical models for psychiatric disorders. I am a Biologist (03), with a PhD in Biochemistry (08) obtained at Unicamp. My postdoctoral experience was at the Max Planck Institute of Psychiatry in Germany (08-10) and at the University of Cambridge in the United Kingdom (10-12), where I also led the Mass Spectrometry Unit at the Cambridge Center for Neuropsychiatric Research (CCNR). At the same time, I was a consultant for Psynova Neurotech Ltd. I was Elected Affiliated Member of the Brazilian Academy of Sciences (17-21) and Affiliated Member of the Academy of Sciences of the State of São Paulo (19-23). I am also a founding member of BrProt and board member of BrMass. I was elected to the board of the Human Proteome Organization (15-17) and I have been a member of the Human Brain Proteome Project Steering Committee since 2015. I am an Associate Editor of npj Schizophrenia (Nature), member of the editorial board of 7 other scientific journals and a permanent editor of a book series entitled "Proteomics, Metabolomics, Interactomics and Systems Biology" by Springer-Nature. I gave more than 60 oral presentations at international conferences, including Plenary Speaker, Keynote Speaker and Chair. H34 (ISI) and H43 (Scholar) with more than 6600 citations (Scholar). (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Depression due to inflammation |
| Depresión por inflamación |
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Schizophrenia is a severe mental disorder that affects 0.7% of the worldwide population. The interactions between genetic and environment factors seem to be responsible for alterations in neurodevelopment, resulting in the manifestation of schizophrenia in late adolescence to early adulthood. The pathophysiology of schizophrenia is highly complex and involves several neurotransmission sys…
This equipment will enable the establishment of a lipidomic platform for the study of brain diseases, in particular psychiatric disorders. This equipment will be combined with the mass spectrometer also funded by FAPESP (2014 / 10068-4). (AU)
Schizophrenia is among the most disabling diseases of humankind, affecting 1% of the world's population (in Brazil, almost 2.5 million people are affected). One of the biggest hurdles faced by most patients is the poor efficacy of current antipsychotic medication. This stems from the lack of understanding of schizophrenia's pathobiology and the lack of biomarkers and biological mechanisms…
Rapidly, SARS-CoV-2 viral infections became pandemic, leading several countries to a state of public calamity. Using a non-hypothesis driven methodology based on proteomics and metabolomics, the present project aims to identify the molecular mechanisms involved in SARS-CoV-2 infection in macrophage and pulmonary epithelium cultures as well as cultured neurons and astrocytes. We will also …
nd to discover possible therapeutic agents for this process. Studies indicate that the modulation of the endocannabinoid system in oligodendrocytes can affect important biological processes. Thus, the aim of this project will evaluate several pharmacological manipulations of the endocannabinoid system in human culture of oligodendrocytes (MO3.13), and in the differentiation process of the…
A mass spectrometer is the central core of a proteomics laboratory. Proteomic analyses depend 100% on a mass spectrometer. The equipment proposed is pivotal for the success of the project 13/08711-3 funded by FAPESP. All steps proposed by this project as well as collaborations regarding proteomic analyses in all senses depend heavily on this equipment: protein identification, quantificati…
(Only some records are available in English at this moment)
Schizophrenia is a chronic and complex neuropsychiatric disorder with typical onset in early adulthood and with a prevalence of 1% in the adult population. It is a multifactorial and non-homogeneous disorder, caused by disturbances in specific genes and environmental insults during early neurodevelopment, leading to neurophysiological changes over time. Despite all scientific advances in …
Schizophrenia is a debilitating mental disorder, which affects approximately 1% of the world population, bringing a significant social and economical burden. Disease symptoms generally manifest in young adults, when the neurodevelopment is at its end. Although many studies have been conducted to understand the origin of schizophrenia, little is known about the molecular mechanisms involve…
The present project aims to create and develop a multimedia communication strategy for the thematic project "From basic understanding to clinical biomarkers for schizophrenia: a multidisciplinary study focused on neuroproteomics", supported by the São Paulo Research Foundation (FAPESP) and developed at the Laboratory of Neuroproteomics (LNP - State University of Campinas). During the term…
There is still little understanding of the molecular mechanisms of SARS-CoV-2 infection, especially in the Central Nervous System (CNS). This makes it difficult to halt the rapid spread of the virus, which has taken on pandemic dimensions, leading many countries, including Brazil, to declare a state of public calamity. There is evidence that SARS-CoV2 is hosted not only in the respiratory…
(Only some records are available in English at this moment)
The brain is the most cholesterol-rich organ, accounting for 25% of the total cholesterol present in the human body, and is essential for synaptic transmission. Within the brain, myelin contains the majority of cholesterol, representing 70%, with the other 30% being present in the membranes of neurons and glial cells. Disturbances in cholesterol metabolism and levels are a risk factor for…
The pathophysiology of schizophrenia (SCZ) is highly complex and involves several neurotransmission systems. Recently, the endocannabinoid system has been investigated in this field, and cannabinoids (endocannabinoids, phytocannabinoids and synthetic cannabinoids) seem to be a potential target to treat SCZ. Additionally, abnormalities in glia cells - especially oligodendrocytes (OLs) - pl…
Chemical cross-linking coupled to mass spectrometry (XLMS) is a great tool to investigate protein-protein interaction. In this technique, in vitro complexes are reacted with cross-linkers and the linkage sites are latter reliably identified by mass spectrometry. Although this technique has been used successfully to map protein interactions in cases of stable, high affinity complexes, the …
Schizophrenia is an incurable mental disorder that affects 1% of the world population and is among the most disabling human diseases. On average, 70% of patients abandon medication due to its low efficacy and the presence of severe side effects. To change these conditions, it is necessary to understand the pathophysiology of schizophrenia at the molecular level. Besides the long-establish…
(Only some records are available in English at this moment)
| 3 / 3 | Ongoing research grants |
| 5 / 4 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 33 / 28 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 4 / 4 | Completed scholarships abroad |
| 49 / 43 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID